Xencor, Inc.

Xencor Inc. is a biopharmaceutical company dedicated to the development of engineered monoclonal antibodies for the treatment of cancer and autoimmune disorders. Its pioneering approach involves engineering the Fc (fragment crystallizable) domain of antibodies, utilizing XmAb technology to enhance potency, regulate immune cell engagement, and improve half-life. Xencor’s products gain recognition for their potential to optimize therapeutic profiles by increasing immune system activity and improving patient outcomes. Targeting key areas in biotechnology, Xencor collaborates with a range of industry leaders to advance and commercialize its innovative drug candidates. The company's commitment to scientific excellence enables the development of next-generation therapies that have a significant impact on healthcare. With its strategic focus on complex diseases, Xencor plays a vital role in the pharmaceutical industry, contributing to the innovation and expansion of treatment possibilities. Based in California, the company continues to be a pivotal player in advancing medical treatments through its collaboration and research endeavors.